

In the Specification:

Page 8, rewrite lines 19 to 24 as follows:

HIV seropositive patients' PBMC have been incubated with the selected peptides (plain bars) or the corresponding lipopeptides (dotted bars). The activation of the specific CTLs has been followed by using the ELISPOT® test specific for γ -interferon. The codes allocated to each patient and their HLA type are indicated. The data are representative for two independent experiments.

Page 19, rewrite lines 5 to 9 as follows:

- for monopalmitoylpeptides, a 12.5 mm x 250 mm column loaded with a stationary phase of C18 (0.03, 5 μ m) Hyperprep Hypersil type eluted at 5ml/min,
- for dipalmitoylpeptides, a 12.5 mm x 250 mm column loaded with ZORBAX® C3 (0, 03, 5 μ m) and eluted at 4ml/min.